The European Commission reversed its decision and will allow Takeda to retain the rights to an inflammatory bowel disease candidate it was supposed to divest as part of its 2018 acquisition of Shire.
What you should know:
1. Takeda was supposed to divest its IBD candidate, SHP 647.
2. Takeda requested to waive the divestment procedure after the development of several circumstances during the divestiture process.
3. The commission reversed its decision because:
New IBD drugs emerged with better safety and efficacy profiles than Takeda and Shire's candidate
Some studies on SHP 647 yielded negative results
Researchers had issues recruiting patients to trials for SHP 647
4. Takeda and Shire now regained the rights to the drug candidate.